Management of tubal ectopic pregnancy with methotrexate in the setting of symptomatic Coronavirus disease 2019 (COVID-19): A case report.
Journal
Facts, views & vision in ObGyn
ISSN: 2032-0418
Titre abrégé: Facts Views Vis Obgyn
Pays: Belgium
ID NLM: 101578773
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
ppublish
Résumé
Coronavirus Disease 2019 (COVID-19) represents a complex therapeutic challenge. As the pandemic progresses, patients are presenting with ectopic pregnancies (EPs) and symptomatic COVID-19. We present the management of a patient with multiple medical comorbidities and tubal EP in the setting of severe symptomatic COVID-19 infection where all management options were precluded. Case report with literature review of management of tubal EP in the setting of severe symptomatic COVID-19 infection. After careful consideration of options, the patient underwent successful medical management with methotrexate while receiving supportive care for COVID-19. Methotrexate proved to be the safest therapeutic option in this patient. Management of patients with severe COVID-19 and gynaecologic emergencies should be individualised and carefully reviewed with evolving knowledge of COVID-19.
Sections du résumé
Background
Coronavirus Disease 2019 (COVID-19) represents a complex therapeutic challenge. As the pandemic progresses, patients are presenting with ectopic pregnancies (EPs) and symptomatic COVID-19.
Objective
We present the management of a patient with multiple medical comorbidities and tubal EP in the setting of severe symptomatic COVID-19 infection where all management options were precluded.
Methods
Case report with literature review of management of tubal EP in the setting of severe symptomatic COVID-19 infection.
Result
After careful consideration of options, the patient underwent successful medical management with methotrexate while receiving supportive care for COVID-19.
Conclusions
Methotrexate proved to be the safest therapeutic option in this patient. Management of patients with severe COVID-19 and gynaecologic emergencies should be individualised and carefully reviewed with evolving knowledge of COVID-19.
Identifiants
pubmed: 34555882
doi: 10.52054/FVVO.13.3.030
pmc: PMC8823271
doi:
Types de publication
Journal Article
Langues
eng
Pagination
273-277Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ultrasound Obstet Gynecol. 2017 Feb;49(2):171-176
pubmed: 27731538
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Rheumatol. 1995 Jun;22(6):1043-7
pubmed: 7674228
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Toxicology. 2009 Feb 27;256(3):183-90
pubmed: 19100307
Am Rev Respir Dis. 1986 Feb;133(2):321-40
pubmed: 3511808
Fertil Steril. 2013 Sep;100(3):638-44
pubmed: 23849842
Reprod Biomed Online. 2017 Apr;34(4):383-391
pubmed: 28131495
Facts Views Vis Obgyn. 2020 May 7;12(1):1
pubmed: 32696018
Hum Reprod. 2013 Jan;28(1):60-7
pubmed: 23081873
Obstet Gynecol. 2018 Mar;131(3):e91-e103
pubmed: 29470343
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Fertil Steril. 1994 Apr;61(4):632-6
pubmed: 8150103
Rev Bras Ginecol Obstet. 2020 Dec;42(12):849-850
pubmed: 33348404
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Arch Intern Med. 1985 Nov;145(11):2035-8
pubmed: 4062454
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Intensive Care Med. 2020 Jun;46(6):1294-1297
pubmed: 32253449
Obstet Gynecol. 2020 Aug;136(2):288-290
pubmed: 32459700
Am J Respir Crit Care Med. 1997 Feb;155(2):395-420
pubmed: 9032171
J Toxicol Sci. 2010 Oct;35(5):653-61
pubmed: 20930460
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Emerg Infect Dis. 2020 Aug;26(8):1839-1841
pubmed: 32384045
Expert Opin Drug Saf. 2009 Jul;8(4):451-8
pubmed: 19538103
Facts Views Vis Obgyn. 2020 Mar 27;11(4):329-335
pubmed: 32322829
Int J Gynaecol Obstet. 2012 Jan;116(1):67-71
pubmed: 22035883